Cargando…
Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genet...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501233/ https://www.ncbi.nlm.nih.gov/pubmed/37501501 http://dx.doi.org/10.1002/cam4.6329 |
_version_ | 1785106076286320640 |
---|---|
author | Iriyama, Chisako Murate, Kenichiro Iba, Sachiko Okamoto, Akinao Goto, Naoe Yamamoto, Hideyuki Kato, Toshiharu Mihara, Keichiro Miyama, Takahiko Hattori, Keiko Kajiya, Ryoko Okamoto, Masataka Mizutani, Yasuaki Yamada, Seiji Tsukamoto, Tetsuya Hirose, Yuichi Mutoh, Tatsuro Watanabe, Hirohisa Tomita, Akihiro |
author_facet | Iriyama, Chisako Murate, Kenichiro Iba, Sachiko Okamoto, Akinao Goto, Naoe Yamamoto, Hideyuki Kato, Toshiharu Mihara, Keichiro Miyama, Takahiko Hattori, Keiko Kajiya, Ryoko Okamoto, Masataka Mizutani, Yasuaki Yamada, Seiji Tsukamoto, Tetsuya Hirose, Yuichi Mutoh, Tatsuro Watanabe, Hirohisa Tomita, Akihiro |
author_sort | Iriyama, Chisako |
collection | PubMed |
description | BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. METHODS: In this study, we extracted cell‐free DNA from the CSF (CSF‐cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet‐digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. RESULTS: Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF‐cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF‐cfDNA detected MYD88 (L265P) and CD79 (Y196) mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18–93 days). CONCLUSIONS: These results suggest that mutation analysis using CSF‐cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform. |
format | Online Article Text |
id | pubmed-10501233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105012332023-09-15 Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases Iriyama, Chisako Murate, Kenichiro Iba, Sachiko Okamoto, Akinao Goto, Naoe Yamamoto, Hideyuki Kato, Toshiharu Mihara, Keichiro Miyama, Takahiko Hattori, Keiko Kajiya, Ryoko Okamoto, Masataka Mizutani, Yasuaki Yamada, Seiji Tsukamoto, Tetsuya Hirose, Yuichi Mutoh, Tatsuro Watanabe, Hirohisa Tomita, Akihiro Cancer Med RESEARCH ARTICLES BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. METHODS: In this study, we extracted cell‐free DNA from the CSF (CSF‐cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet‐digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. RESULTS: Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF‐cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF‐cfDNA detected MYD88 (L265P) and CD79 (Y196) mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18–93 days). CONCLUSIONS: These results suggest that mutation analysis using CSF‐cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform. John Wiley and Sons Inc. 2023-07-27 /pmc/articles/PMC10501233/ /pubmed/37501501 http://dx.doi.org/10.1002/cam4.6329 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Iriyama, Chisako Murate, Kenichiro Iba, Sachiko Okamoto, Akinao Goto, Naoe Yamamoto, Hideyuki Kato, Toshiharu Mihara, Keichiro Miyama, Takahiko Hattori, Keiko Kajiya, Ryoko Okamoto, Masataka Mizutani, Yasuaki Yamada, Seiji Tsukamoto, Tetsuya Hirose, Yuichi Mutoh, Tatsuro Watanabe, Hirohisa Tomita, Akihiro Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title | Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title_full | Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title_fullStr | Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title_full_unstemmed | Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title_short | Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases |
title_sort | utility of cerebrospinal fluid liquid biopsy in distinguishing cns lymphoma from cerebrospinal infectious/demyelinating diseases |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501233/ https://www.ncbi.nlm.nih.gov/pubmed/37501501 http://dx.doi.org/10.1002/cam4.6329 |
work_keys_str_mv | AT iriyamachisako utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT muratekenichiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT ibasachiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT okamotoakinao utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT gotonaoe utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT yamamotohideyuki utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT katotoshiharu utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT miharakeichiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT miyamatakahiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT hattorikeiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT kajiyaryoko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT okamotomasataka utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT mizutaniyasuaki utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT yamadaseiji utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT tsukamototetsuya utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT hiroseyuichi utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT mutohtatsuro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT watanabehirohisa utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases AT tomitaakihiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases |